ORIC-114 + carboplatin + pemetrexed

ORIC-114 + carboplatin + pemetrexed is an investigational, three-drug combination therapy currently being studied for patients with advanced solid tumors harboring alterations in EGFR or HER2, including those with CNS metastases. ORIC-114 is a brain-penetrant, selective, orally bioavailable, irreversible small molecule inhibitor that targets EGFR and HER2 protein alterations—especially exon 20 insertion mutations. Carboplatin is a DNA crosslinking platinum-based chemotherapy, and pemetrexed is an antifolate chemotherapy that inhibits folate-dependent enzymes involved in DNA synthesis. The combination aims to improve antitumor efficacy, particularly in difficult-to-treat, mutation-driven cancers resistant to standard therapies. The combination is in early-phase clinical trials to establish safety, tolerability, and preliminary antitumor activity[1][2][4][7].